missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human HOXA13 (aa 269-319) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (98%), Rat (98%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-139894 (PA5-139894. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
HoxA13 and HoxD13 also bind to other BMP and TGF-beta/Activin-regulated Smad proteins including Smad1 and Smad2, but not Smad4. In humans and mice, loss of HOXA13 function causes defects in the growth and patterning of the digits and interdigital tissues. Analysis of HoxA13 expression reveals a pattern of localization overlapping with sites of reduced Bmp2 and Bmp7 expression in HoxA13 mutant limbs. HoxA13 regulates Bmp2 and Bmp7 expression, providing a link between HoxA13, its target genes and the specific developmental processes affected by loss of HoxA13 function.
Specifications
Specifications
| Accession Number | P31271 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 3209 |
| Name | Human HOXA13 (aa 269-319) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | Hd; homeo box 1 J; homeo box A13; homeobox A13; homeobox protein Hox-1.10; Homeobox protein Hox-1 J; homeobox protein HOXA13; homeobox protein Hox-A13; HO x 1; Hox-1.10; HO x 1 J; HOXA13; hypodactyly; RGD1562483; transcription factor HOXA13 |
| Common Name | HOXA13 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction